ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series

In GI cancers, anaplastic lymphoma kinase (ALK) rearrangements are extremely less frequent than in non–small-cell lung cancer but may be important to offer personalized strategies of treatment in selected patients. Data about the activity and efficacy of ALK inhibitors (ALKi) in GI cancers are scarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambrosini, Margherita, Del Re, Marzia, Manca, Paolo, Hendifar, Andrew, Drilon, Alexander, Harada, Guilherme, Ree, Anne Hansen, Klempner, Samuel, Mælandsmo, Gunhild Mari, Flatmark, Kjersti, Russnes, Hege G., Cleary, James M., Singh, Harshabad, Sottotetti, Elisa, Martinetti, Antonia, Randon, Giovanni, Sartore-Bianchi, Andrea, Capone, Iolanda, Milione, Massimo, Di Bartolomeo, Maria, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200393/
https://www.ncbi.nlm.nih.gov/pubmed/35476549
http://dx.doi.org/10.1200/PO.22.00015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200393/
https://www.ncbi.nlm.nih.gov/pubmed/35476549
http://dx.doi.org/10.1200/PO.22.00015

Ejemplares similares